Merck's Trading Volume Drops 29% to $1.047 Billion Ranking 58th Despite Positive Drug Study Results

On June 24, 2025, Merck's trading volume was $1.047 billion, a 29.23% decrease from the previous day, ranking 58th in the day's stock market. Merck (MRK) rose 0.24%, marking two consecutive days of gains, with a total increase of 1.64% over the past two days.

Merck recently announced positive results from the Phase 3 HYPERION study of Winrevair, a drug designed to treat pulmonary arterial hypertension (PAH). The study met its primary endpoint, demonstrating a significant reduction in the time to clinical worsening events compared to a placebo. This is the third Phase 3 study of Winrevair to show significant efficacy in adults with PAH, following the STELLAR and previous studies.

Winrevair is already approved by the FDA for treating adults with PAH to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The HYPERION study evaluated Winrevair when added to background PAH therapy versus a placebo in newly diagnosed intermediate or high-risk PAH patients. The primary endpoint was the time to clinical worsening, including the need for non-planned PAH-related hospitalization, atrial septostomy, lung transplantation, or PAH deterioration.

Merck is set to hold an investor event to highlight the advancements in its pipeline, including the positive results from the HYPERION study. This event is expected to provide further insights into the company's strategic initiatives and future prospects.